GCSFR Modulators for Selective Cancer Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatment methods, including chemotherapy, radiation therapy, and surgery, have undesirable side effects and varying success rates, and there is a need for new approaches to treat cancer and hematopoietic disorders associated with cellular proliferation.
Innovation Solution
Administration of cytotoxic granulocyte colony-stimulating factor receptor (GCSFR) modulators, which can be administered alone or in combination with chemotherapeutic agents, to achieve a therapeutically effective plasma concentration, thereby treating, preventing, reversing, or slowing the progression of cancer and hematopoietic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy, radiation therapy, or surgery is used to treat cancer, then cancer cells can be targeted, but undesirable side effects occur and success rates vary
Solution Approach 1:
The patent applies local quality by designing GCSFR modulators that specifically target cancer cells expressing the GCSFR receptor, rather than affecting all rapidly dividing cells. This selective targeting is achieved through the molecular structure of the modulator (Formula I) that binds with high affinity to GCSFR, enabling precise local action on tumor cells while sparing normal tissues from harmful effects
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of GCSFR ligands to create novel modulators with optimized binding affinity and cytotoxic properties. The specific molecular parameters in Formula I (substituents R1-R6, linker L1, heterocycle Q) are systematically varied to enhance selectivity and efficacy, representing a fundamental change in the chemical parameters of the therapeutic agent
2Measurement precision
If GCSFR modulators are administered to achieve therapeutic effect, then cancer cells are targeted more precisely, but achieving therapeutically effective plasma concentration requires careful dosing intervals
Solution Approach 1:
The patent incorporates feedback principles by establishing dosing intervals based on the pharmacokinetic profile and half-life of the GCSFR modulator. The dosing regimen is designed to maintain plasma concentrations within the therapeutic window (above EC50 but below toxic levels), with intervals adjusted according to observed efficacy and safety outcomes, creating a closed-loop control system for optimized treatment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of GCSFR modulators effectively targets cancer cells, offering a potentially more precise and less harmful treatment option for cancer and hematopoietic disorders by achieving a therapeutically effective plasma concentration, thereby addressing the limitations of existing cancer treatment methods.
Implementation Method 1
Binding of GCSF to the extracellular Ig-like and CRH domains of the receptor triggers receptor homodimerization with a 2:2 stoichiometry of hGCSF/hGCSFR
Implementation Method 2
The dimerization results in activation of intracellular Janus tyrosine kinase-signal transducers and activators of transcription (Jak-Stat) type signaling cascade
Implementation Method 3
we have surprisingly discovered a new class of GCSF modulators that are cytotoxic to cancer cells
Data Source
AI summary
Some embodiments include methods for treating, preventing, reversing, halting, or slowing the progression of cancer, comprising administering to a subject in need thereof an effective amount of one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, wherein at least one of the chemotherapeutic agents is a cytotoxic granulocyte colony-stimulating factor receptor (GCFR) modulator. Methods are also disclosed for treating, preventing, reversing, halting, or slowing the progression of a hematopoietic disorder, comprising administered a therapeutically effective cytotoxic amount of a GCFR modulator to a subject in need thereof.